Home

Abraham Ceesay

CIK 1722140 · Chief Executive Officer · last filed 2026-09-09

Abraham Ceesay is a Chief Executive Officer who has filed 40 SEC Form 4 insider transactions across 6 companies since 2018. The most recent filing shows the insider sold $374.5K of RAPP on Sep 9, 2026. Across all open-market trades the lifetime net is −$11.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $24.5M across reported positions. 7 SEC filings were submitted jointly with Pacira BioSciences, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$24.52M

Companies

6

Total Filings

40

Lifetime Open-Market Net

-$11.31M

Filer Profile

Reported Address
C/O SCPHARMACEUTICALS, INC.
2400 DISTRICT AVENUE SUITE 310
BURLINGTON, MA 01830
Related Filers
Pacira BioSciences, Inc. — 7 joint filings, latest 2026-06-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RAPP Chief Executive Officer 541,775 $43.62 $23.63M -$7.99M 15 2026-09-09
CRL Director 2,384 $278.26 $663.4K $0 2 2026-05-11
PCRX Director 9,039 $25.36 $229.2K -$64.0K 4 2025-09-08
Cerevel Therapeutics Holdings, Inc. (CERE) Delisted President 19,210 $44.96 $863.7K -$3.26M 6 2023-02-08
Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted President — $18.07 — $0 1 2021-06-03
scPharmaceuticals Inc. (SCPH) Delisted Chief Operating Officer — $5.67 — $0 1 2018-01-19

Recent Filings

40 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-09 RAPP Sell (S) −8,210 -$374.5K EDGAR
2026-08-26 RAPP Sell (S) −18,921 -$938.0K EDGAR
2026-08-12 RAPP Sell (S) −51,499 -$2.43M EDGAR
2026-07-29 RAPP Sell (S) −2,210 -$93.1K EDGAR
2026-07-15 RAPP Sell (S) −8,210 -$328.4K EDGAR
2026-07-01 RAPP Sell (S) −8,220 -$327.4K EDGAR
2026-06-29 RAPP Notice (144) −99,480 -$4.02M EDGAR
2026-06-12 PCRX Notice (144) −9,039 -$210.4K EDGAR
2026-05-11 CRL Grant (A) +1,438 $255.4K EDGAR
2026-02-19 RAPP Sell (S) −10,916 -$320.4K EDGAR
Showing 1–10 of 40
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.